Introduction
============

Early detection of tumors is crucial in cases of gastrointestinal stromal tumor (GIST) because larger tumor diameters tend to result in worse prognoses [@JR262-1]. It is also important to identify GISTs at a smaller size, because even small GISTs have malignant potential with poor prognosis [@JR262-2]. Each case of GIST is now subjected to surgery if possible. Thus, differentiating between GISTs and other submucosal tumors (SMTs) is essential. Leiomyomas, which are benign mesenchymal tumors located mainly in the muscular propria of the gastrointestinal tract, are difficult to differentiate from GISTs because of similar features in origin, although electron microscopy with immunohistochemistry may reveal differences [@JR262-3]. Moreover, it is difficult to distinguish GISTs from leiomyomas using imaging techniques in daily practice. Serum biomarkers for GIST have not yet been established, although GISTs express specific proteins in tissues, such as c-kit and CD34 [@JR262-4]. Immunohistochemical analysis (i. e., c-kit staining for GIST) has furthered the accuracy of differential diagnosis of submucosal tumors [@JR262-1]. Although 95 % of GIST tissues express c-kit protein, the other subset presents low or negative expression [@JR262-5]. Most cases of c-kit-negative GIST arise in the stomach [@JR262-6]. Therefore, c-kit protein is not perfect for diagnosis of GIST, especially cases of gastric GIST. Although detection of serum c-kit by flow cytometry was reported as useful for diagnosis of GIST measuring more than 2 cm in diameter, the method has limitations in that it cannot be used to detect GIST smaller than 2 cm in diameter and cut-off levels of c-kit are not optimized in this system [@JR262-7]. Genetic mutations such as *KIT* and *PDGFRA* also are associated with GIST [@JR262-1]. Approximately 10 % to 15 % of GIST, however, do not have mutations in either *KIT* or *PDGFRA* [@JR262-6].

MiRNAs have been shown to serve as biomarkers of malignant and benign diseases [@JR262-8]. MiRNAs are key molecules in post-transcriptional regulation of gene expression, and alteration of miRNA expression is related to aberrant gene expression. Tumorigenesis, tumor progression, fibrosis, and tumor immunity have been described in the context of disordered miRNA expression. Accordingly, miRNA expression was previously examined in various sarcoma cases including GIST [@JR262-9] and uterine leiomyoma cases [@JR262-10]. A comparison of miRNA expression profiles between GISTs and leiomyosarcomas also was performed in a gastroenterology context [@JR262-11]. In addition, miRNAs with altered expression levels have been identified in patients with osteosarcoma [@JR262-12]. However, miRNAs specific to small GISTs classified as low risk have not been identified. Because basic approaches comparing GIST and leiomyoma may provide clinically significant findings, we aimed to identify miRNAs as biomarkers of GIST by comparing low-risk GISTs and leiomyomas of the stomach in humans.

Patients and methods
====================

Study design
------------

MiRNA expression was measured in nine GIST samples and seven leiomyoma samples, which were diagnosed histopathologically and acquired using a modified version of the submucosal tunneling biopsy (STB) technique [@JR262-13]. STB provides the advantage of sufficient tumor specimen acquisition without contamination under direct vision. Total RNAs were extracted from these tissues and analyzed for the expression of 2,555 miRNAs by microarray, comparing GISTs with leiomyomas.

Ethics
------

This study was approved by the Clinical Ethics Committee of Kagawa University Hospital. All patients provided written informed consent to undergo STB and participate in the study. The use of STB was previously approved by the same ethics committee.

Clinical and pathologic information
-----------------------------------

Clinical information about the patients included gender, clinical presentation, radiologic and endoscopic findings, laboratory findings, and the pathologic characteristics of the tumors ([Table 1](#TB262-1){ref-type="table"}). Immunohistochemical analysis of tissue samples was performed for c-kit, SMA, and S-100 proteins. Mitotic counts per 50 high-power fields were estimated by expert pathologists. GISTs were classified according to the Fletcher [@JR262-1] classification, including mitotic counts and maximum tumor size.

###### Patient profile.

  Serial number   Age   Gender   Tumor location   Layer   Maximum tumor size (mm)   Echogenicity on EUS
  --------------- ----- -------- ---------------- ------- ------------------------- ---------------------
   1              76    Female   Stomach          MP      32                        Hypo
   2              41    Male     Stomach          MP      15                        Hypo
   3              72    Female   Stomach          MP      14                        Hypo
   4              82    Female   Stomach          MP      13                        Hypo
   5              73    Male     Rectum           MP      25                        Hypo
   6              70    Male     Stomach          MP      15                        Hypo
   7              48    Male     Stomach          MP      20                        Hypo
   8              52    Male     Stomach          MP      7.5                       Hypo
   9              67    Female   Stomach          MP      21                        Hypo
  10              54    Female   Stomach          MP      22                        Hypo
  11              53    Male     Stomach          MP      15                        Hypo
  12              66    Male     Stomach          MP      21                        Hypo
  13              63    Male     Stomach          MP      20                        Hypo
  14              69    Female   Esophagus        MP      30                        Hypo
  15              39    Female   Stomach          MP      10                        Hypo
  16              44    Male     Stomach          MP      10                        Hypo

EUS: endoscopic ultrasonography; MP: muscularis propria;

Submucosal tunneling biopsy
---------------------------

Tissue samples were obtained from patients using STB [@JR262-13] [@JR262-14]. This technique enables endoscopists to obtain core biopsy specimens of endoluminal subepithelial tumors under direct vision. We believe that specimens acquired with this technique are suitable for miRNA analysis because endoscopists can exclude other tissues, such as connective and adipose tissues and smooth muscle, under direct vision of the target tumors. This methodology consists of four procedures: 1) creation of the entry; 2) submucosal endoscopy with a mucosal flap (SEMF) [@JR262-15]; 3) acquisition of core specimen; and 4) clip closure of the entry. These steps are shown in [Fig. 1](#FI262-1){ref-type="fig"} as a schema. In short, mucosal incision using a needle knife (KD-441Q; Olympus, Tokyo, Japan), based on the endoscopic submucosal dissection (ESD) technique, was performed to create a 10-mm opening flap, followed by two-point marking of the normal mucosa around the lesion with 10-mm margins. Second, a submucosal tunnel was created by submucosal dissection toward the tumor. After the tumor was identified and exposed under direct vision, a core specimen measuring 1 to 4 mm was acquired with biopsy forceps (Radial Jaw^TM^ 4 Standard Capacity; Boston Scientific). Finally, the opening flap was sutured with hemoclips (HX-610 -- 135; Olympus, Tokyo, Japan). All procedures were performed by an experienced endoscopist (H.K.; more than 200 gastric ESD cases were performed successfully).

![ Schematic protocol for submucosal tunneling biopsy. The protocol consists of four procedures: 1) creation of the entry; 2) submucosal endoscopy with a mucosal flap (SEMF), in which the tumor is identified via a submucosal tunnel; 3) core specimen (1 -- 4 mm in size) acquisition using biopsy forceps; and 4) clip closure of the entry.](10-1055-s-0034-1393077-i262ei1){#FI262-1}

MiRNA analysis by microarray
----------------------------

Total RNA was extracted from tumor tissues using the miRNeasy Mini Kit (Qiagen, Venlo, Netherland), as previously described [@JR262-16]. RNA was labeled using a miRCURY Hy3 Power Labeling Kit (Exiqon, Vedbaek, Denmark) and hybridized on a human miRNA Oligo chip, version 20.0 (Toray, Tokyo). Scanning was conducted with the 3D-Gene Scanner 3000 (Toray). 3D-Gene extraction software (ver. 1.2, Toray) was used to read the raw intensity of the image. The raw data were analyzed with GeneSpringGX (ver. 10.0, Agilent Technologies, Santa Clara, CA) and quantile normalized. The microarray data obtained in this study are registered at the NCBI Gene Expression Omnibus (GEO) with the accession number GSE63453.

We calculated the fold changes in miRNA expression level between GIST and leiomyoma samples. Hierarchical clustering was accomplished using the farthest neighbor method. The uncentered Pearson\'s product-moment correlation coefficient was used as a metric. Statistical analysis was performed using unpaired t-tests. *P* values \< 0.05 were recognized as significant.

Real-time qPCR
--------------

Reverse transcription and real-time quantitative polymerase chain reaction (qPCR) were performed for miRNAs using the ΔΔCT method to confirm their increased expression in GISTs compared to leiomyomas, as shown in the microarray analysis. Taqman^®^ microRNA Assays (Life technologies, Carlsbad, CA) were adapted to determine the expression level of miRNAs with U6 as an internal control (Assay ID: 001093 for U6; 001187 for miR-140 -- 5p; 002234 for miR-140 -- 3 p). MiRNAs were reverse transcribed using the Taqman^®^ microRNA Reverse Transcription Kit (Life Technologies) according to the manufacturer's protocol. In short, total RNA extracted using the miRNeasy Mini Kit (Qiagen) was diluted to 1.0 ng/μl. Reverse transcription was prepared in 15 μl reaction consisting of 5 μl of RNA, 3 μl of 5 x RT primer and 12 μl of reverse transcripition master mix. As a result, 0.33 ng/μl of cDNA was produced. The final PCR reaction, performed in a 20-μl-volume tube, consisted of 2 μl of cDNA (0.66 ng), 1 μl of 20 × qPCR assay, 7 μl of nuclease-free water and 10 μl of Taqman^®^ Fast Advanced Master Mix according to the manufacturer's protocol. The cDNA was amplified and quantified using StepOne Plus^TM^ (Life technologies). MiRNA expression levels were standardized to U6.

Results
=======

Clinical and pathologic features
--------------------------------

The average maximum diameter of the nine GISTs was 18.05 mm, which was smaller than that of the seven leiomyomas (18.29 mm). Three of the patients with GIST presented tumors larger than 2.0 cm in diameter, and six of the nine patients presented smaller tumors. The STB method was performed successfully, providing large specimens for histopathologic assessment and total RNA extraction ([Table 2](#TB262-2){ref-type="table"}). The 9 GISTs were assigned scores of 5 (very low risk) and 4 (low risk), according to the Fletcher classification ([Table 3](#TB262-3){ref-type="table"}).

###### Sampling data obtained by submucosal tunneling biopsy.

  Serial number   Technical performance   Acquired specimen size (mm)   Clinical diagnosisaccording to FletcherClassification
  --------------- ----------------------- ----------------------------- -------------------------------------------------------
   1              Success                 1.4 × 1.2                     GIST, low
   2              Success                 1.9 × 0.9                     GIST, very low
   3              Success                 2.6 × 1.4                     GIST, very low
   4              Success                 1.1 × 0.6                     GIST, very low
   5              Success                 2.1 × 1.1                     GIST, low
   6              Success                 2.2 × 2.1                     GIST, very low
   7              Success                 1.4 × 0.9                     GIST, low
   8              Success                 2.1 × 0.9                     GIST, very low
   9              Success                 4.5 × 3.5                     GIST, low
  10              Success                 2.4 × 2.0                     Leiomyoma
  11              Success                 2.4 × 1.5                     Leiomyoma
  12              Success                 1.9 × 1.6                     Leiomyoma
  13              Success                                               Leiomyoma
  14              Success                                               Leiomyoma
  15              Success                 4.0 × 2.5                     Leiomyoma
  16              Success                                               Leiomyoma

GIST, gastrointestinal stromal tumor

###### Details of pathology.

  Serial number   Pathologic diagnosis   Mitotic counts (/ 50 HPF)   Ki67(M1B index)   c-kit   α-SMA   FletcherClassification
  --------------- ---------------------- --------------------------- ----------------- ------- ------- ------------------------
   1              GIST                   \< 2                        \< 3 %            +       --      GIST, low
   2              GIST                   none \< 2                   1 %                +      --      GIST, very low
   3              GIST                   none \< 1                    \< 2 %            +      --      GIST, very low
   4              GIST                   none \< 1                   1 -- 2 %          +       --      GIST, very low
   5              GIST                   none \< 1                   5 %               +       --      GIST, low
   6              GIST                   none \< 1                   none              +       --      GIST, very low
   7              GIST                   none \< 1                   \< 5 %            +       --      GIST, low
   8              GIST                   \< 5                        1 -- 2 %          +       --      GIST, very low
   9              GIST                   \< 5                        \< 5 %            +       --      GIST, low
  10              Leiomyoma              none                        none              --      +       Leiomyoma
  11              Leiomyoma              none                        none              --      +       Leiomyoma
  12              Leiomyoma              none                        \< 1 %            --      +       Leiomyoma
  13              Leiomyoma              none                        \< 1 %            --      +       Leiomyoma
  14              Leiomyoma                                                            --      +       Leiomyoma
  15              Leiomyoma                                                            --      +       Leiomyoma
  16              Leiomyoma                                                            --      +       Leiomyoma

GIST, gastrointestinal stromal tumor.

MiRNA analysis
--------------

To investigate candidate miRNAs as biomarkers of GIST, we screened the miRNA expression levels in GIST and leiomyoma tissues. An unsupervised hierarchical clustering analysis revealed that miRNAs in GISTs clustered separately from those in leiomyomas ([Fig. 2](#FI262-2){ref-type="fig"}). We identified 39 miRNAs that were differently expressed among 2,555 miRNAs examined ([Table 4](#TB262-4){ref-type="table"}). In particular, 13 miRNAs were upregulated and 26 were downregulated in GISTs compared to leiomyomas. Upregulation of the miR-140 family showed the largest fold change, approximately 20-fold higher in GISTs compared to leiomyomas.

![ Hierarchical clustering of miRNA expression profiles extracted from GIST and leiomyoma specimens acquired by submucosal tunneling biopsy. The samples are arranged in columns, and the miRNAs are arranged in rows. The tree on the left represents miRNA clustering. The tree above the heatmap shows sample clustering. The serial numbers of the samples are noted in the tree. Red squares around the serial numbers indicate the samples that were analyzed for miR-140-5 p and -3 p expression by real-time qPCR. Heatmaps show the relative expression intensity for each miRNA, in which the base-2 logarithm of the intensity is median-centered for each row. The color-coding is indicated as a horizontal bar at the left shoulder of the heatmap. ](10-1055-s-0034-1393077-i262ei2){#FI262-2}

###### miRNA profiling of GIST compared to leiomyoma**.**

  Name              Fold change (GIST/leiomyoma)   SD      *P* [\*](#FN262-1){ref-type="table-fn"}   Chromosomal location
  ----------------- ------------------------------ ------- ----------------------------------------- ----------------------
  miR-140 -- 5 p    20.08                          15.82   0.0099                                    16
  miR-140 -- 3 p    16.82                          11.39   0.0040                                    16
  miR-181a-5 p      6.18                           5.10    0.0256                                    1
  miR-199a-5 p      3.45                           2.52    0.0322                                    19
  miR-3151 -- 5 p   2.58                           1.07    0.0044                                    8
  miR-483 -- 5 p    2.56                           0.92    0.0029                                    11
  miR-4436b-3 p     1.77                           0.66    0.0273                                    2
  miR-6756 -- 5 p   1.71                           0.63    0.0271                                    11
  miR-3917          1.69                           0.61    0.0228                                    1
  miR-26b-3 p       1.67                           0.70    0.0488                                    2
  miR-4776 -- 5 p   1.65                           0.54    0.0188                                    2
  miR-3175          1.57                           0.47    0.0136                                    15
  miR-6127          1.56                           0.34    0.0241                                    1
  miR-1909 -- 3 p   0.69                           0.22    0.0378                                    19
  miR-4745 -- 5 p   0.66                           0.32    0.0288                                    19
  miR-3195          0.64                           0.10    0.0178                                    20
  miR-718           0.62                           0.22    0.0424                                    X
  miR-4535          0.61                           0.08    0.0032                                    22
  miR-4467          0.58                           0.25    0.0372                                    7
  miR-5090          0.56                           0.22    0.0500                                    7
  miR-6746 -- 3 p   0.55                           0.34    0.0413                                    11
  miR-4443          0.49                           0.13    0.0432                                    3
  miR-4687 -- 5 p   0.43                           0.11    0.0412                                    11
  miR-3135b         0.43                           0.21    0.0046                                    6
  miR-5010 -- 5 p   0.36                           0.24    0.0203                                    17
  miR-497 -- 5 p    0.31                           0.30    0.0074                                    17
  miR-222 -- 3 p    0.29                           0.35    0.0364                                    X
  miR-378f          0.25                           0.17    0.0072                                    1
  miR-28 -- 3 p     0.23                           0.25    0.0050                                    3
  miR-422a          0.23                           0.18    0.0206                                    15
  miR-378 d         0.22                           0.17    0.0093                                    4
  miR-378c          0.22                           0.17    0.0074                                    5
  miR-378e          0.22                           0.18    0.0090                                    5
  miR-378 g         0.22                           0.21    0.0110                                    1
  miR-378i          0.21                           0.16    0.0084                                    22
  miR-378a-3 p      0.19                           0.13    0.0102                                    5
  miR-195 -- 5 p    0.19                           0.24    0.0024                                    17
  miR-133a-3 p      0.04                           0.03    0.0016                                    18
  miR-133b          0.03                           0.02    0.0001                                    6

GIST, gastrointestinal stromal tumor

Unpaired t-tests

Real-time qPCR
--------------

Reverse transcription and real-time qPCR were performed for miR-140 -- 5 p and -- 3 p, the two miRNAs that presented the most difference in their expression level between GIST and leiomyoma samples in the microarray analysis. The expression level of miR-140 -- 5 p compared to U6 (ΔCT ± SD) was -- 1.255 ± 1.891 for GISTs and 3.545 ± 1.114 for leiomyomas (*P* = 0.0008); thus, the relative expression level (2^-ΔΔCT^) was 27.86 times greater in GISTs compared to leiomyomas as shown in [Fig. 3](#FI262-3){ref-type="fig"}. In the case of miR-140 -- 3 p, the ΔCT value was 5.167 ± 1.886 in GISTs and 8.780 ± 2. 337 in leiomyomas (*P* = 0.0304), revealing a 12.24 times greater. Samples numbered 3, 4, 6 -- 10, 12, 14, 15, and 16 were analyzed by real-time qPCR for miR-140 family miRNAs; the other samples were not assessed because no total RNAs remained after microarray analysis.

![ Real-time qPCR for miR-140 -- 5 p and -- 3 p in GISTs compared to leiomyomas. **a**The relative expression level (2^-ΔΔCT^) of miR-140-5 p and -3 p was higher in GISTs than leiomyomas (27.86 times and 12.24 times, respectively). **b** The expression level of the miRNAs is shown as the average ΔC~T~ ± SD. Six GIST and five leiomyoma samples were analyzed using real-time qPCR because no total RNA remained for other GIST or leiomyoma tissues after microarray analysis. \*The *P*values were calculated using an unpaired t-test.](10-1055-s-0034-1393077-i262ei3){#FI262-3}

Discussion
==========

The aim of the current study was to identify differences between small GISTs and leiomyoma through the investigation of miRNA expression patterns in human cases, because small GISTs and leiomyomas are difficult to differentially diagnose using contrast-enhanced CT scanning or endoscopic ultrasonography. Our main findings demonstrated that among 2,555 miRNAs, 13 miRNAs were upregulated and 26 miRNAs were downregulated in GISTs compared to leiomyomas. Among these, the miR-140 family was upregulated around 20 times greater in GISTs than in leiomyomas. Moreover, miRNAs extracted from tumor tissues differentially clustered between GISTs and leiomyomas. Real-time qPCR confirmed greater than a 10 -- to 20-fold expression of the miR-140 family in GISTs compared to leiomyomas, in accordance with the microarray analysis.

Although EUS-guided fine needle aspiration (EUS-FNA), which has emerged as a standard method for sampling submucosal tumors, has the advantages of being rapid and convenient, its diagnostic yield is generally limited because of too little material for immunohistochemistry and technical issues [@JR262-17] [@JR262-18]. Accordingly, novel techniques with a greater diagnostic yield are needed to optimize tissue sampling. We have developed a novel sampling method, submucosal tunneling biopsy by using submucosal endoscopy, for gastric SMTs [@JR262-13] [@JR262-14]. The method that is applied to create a submucosal tunnel with a safety mucosal flap [@JR262-15] enables us to obtain one core specimen for immunohistologic analysis, visualization of the tumor surface [@JR262-19], identification of the layer of origin, and management of hemostasis under endoscopic vision. In addition, histologic analysis demonstrated that the acquired samples were pure specimens without contamination [@JR262-20] and provided suitable SMT samples for miRNA analysis in the current study. The limitation of this method is that the potential for larger and deeper fibrotic changes of mucosa following the procedure. Fibrotic adhesion between layers of mucosa may make it difficult to perform secondary endoscopic resection of the tumor [@JR262-21]. Submucsal endoscopy, an endoscopic submucosal tunneling method which is recognized worldwide for use in oral endoscopic myotomy (POEM) [@JR262-22] in patients with achalasia, has opened up the new discipline of submucosal endoscopic surgery. Through what are best termed submucosal operations, we are exploring the full potential of the outstanding diagnostic and therapeutic interventions possible in the submucosal space [@JR262-21]. Thirteen miRNAs among 2,555 examined, including miR-140 -- 5 p and miR-140 -- 3 p, were upregulated in GISTs compared to leiomyomas. The miR-140 family, which presented the largest change (approximately 20 times more highly expressed in GISTs compared to leiomyomas), is expressed in mesenchymal tissues such as articular cartilage in chondrogensis [@JR262-23], human airway smooth muscle [@JR262-24], and osteosarcoma [@JR262-25]. MiR-140 has also been reported to regulate skeletal development. In two past studies that also reported upregulation of miR-140 family in GIST, 668 to 725 probes for miRNAs were used in microarray analysis without clear information about tumor diameter and validation of miR-140 -- 5 p/3 p expression by real-time qPCR [@JR262-9] [@JR262-11]. Although the significance of miR-140 upregulation in GISTs remains unclear, this is the first report to identify an association between small GISTs with diameters \~ 20 mm and miR-140 that used reliable human samples and array analysis on up to 2,555 miRNAs.

MiRNA profiling revealed miRNAs that were differentially clustered between GISTs and leiomyomas, despite the histologic similarities between these tumors. Typically, GISTs cannot be distinguished from leiomyomas without immunohistochemical examination and electron microscopy analysis [@JR262-3]. Although miR-140 -- 3 p has been shown to be a poor serum biomarker in patients with osteosarcoma [@JR262-12], the miR-140 family, which presented the largest change among the 39 miRNAs identified in this array analysis, should be evaluated as serum biomarkers of GIST. In addition, future studies should investigate how cartilage-specific miRNAs function in GIST and how these miRNAs contribute to the differentiation and proliferation of several mesenchymal tissues.

In conclusion, the expression profiles of the miR-140 family differed between GISTs and leiomyomas among the 2,555 miRNAs examined. MiR-140-5 p and -3 p may serve as specific biomarkers of small GISTs with diameters of approximately 20 mm for differential diagnosis of GISTs and leiomyomas.
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